Viracta Therapeutics has announced the closure of its NAVAL-1 clinical trial for Nana-val in relapsed/refractory EBV+ lymphomas to conserve resources while exploring strategic alternatives, including potential mergers or sales. The company reassured stakeholders that the trial’s closure was not due to safety concerns and emphasized its commitment to maximizing shareholder value through various strategic options.
https://finance.yahoo.com/news/viracta-therapeutics-explores-strategic-options-215758533.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.